Wang Bin, Lin Hong, Xia Rubin, Lin Shuiqin, Li Zhiling
Reproductive Center, The First Affiliated Hospital of Shantou University Medical College, Shantou University, Shantou, Guangdong 515041, P.R. China.
Department of Pathology, The First Affiliated Hospital of Shantou University Medical College, Shantou University, Shantou, Guangdong 515041, P.R. China.
Exp Ther Med. 2024 May 31;28(2):307. doi: 10.3892/etm.2024.12596. eCollection 2024 Aug.
At present, safety of letrozole administration as an ovulation-inducing drug still remains controversial. Investigation of the safety of letrozole use for the induction of ovulation in the Chinese population is scant. The present study aimed to fill this gap. Data concerning mothers using letrozole and birth outcomes of their singleton offspring were collected as the letrozole group (n=194), equivalent data from mothers using non-letrozole drugs and their singleton offspring were included as the non-letrozole group (control, n=154). Birth outcomes, congenital anomalies and neonatal complications were compared and analyzed between the two groups. Univariate analysis, Spearman's rank correlation analysis and the logistic regression model were utilized. For birth outcomes, the percentage of caesarean section deliveries in the letrozole group was lower than the non-letrozole group (43.8 vs. 56.4%, P=0.019). For congenital anomalies, no significant difference was found between the two groups (all P>0.05). The statistical P-value for the correlation between the maternal use of letrozole and neonatal complications was marginal (P=0.051). Results from the logistic regression analysis confirmed that maternal use of letrozole was not a significant contributor for neonatal complications, independent of statistical adjustment [crude odds ratio (OR), 1.436; 95% confidence interval (CI), 0.803-2.569; P=0.223 vs. adjusted OR, 1.406; 95% CI, 0.748-2.643; P=0.290). The results of the present study suggested that maternal use of letrozole for ovulation induction does not associate with poorer birth outcomes or increased risk of congenital anomalies and neonatal complications.
目前，来曲唑作为促排卵药物使用的安全性仍存在争议。在中国人群中，关于来曲唑用于促排卵安全性的研究较少。本研究旨在填补这一空白。收集使用来曲唑的母亲及其单胎后代的出生结局数据作为来曲唑组（n = 194），将使用非来曲唑药物的母亲及其单胎后代的等效数据作为非来曲唑组（对照组，n = 154）。比较并分析两组之间的出生结局、先天性异常和新生儿并发症。采用单因素分析、Spearman秩相关分析和逻辑回归模型。对于出生结局，来曲唑组剖宫产分娩的百分比低于非来曲唑组（43.8% 对56.4%，P = 0.019）。对于先天性异常，两组之间未发现显著差异（所有P>0.05）。母亲使用来曲唑与新生儿并发症之间的相关性统计P值接近临界值（P = 0.051）。逻辑回归分析结果证实，母亲使用来曲唑并非新生儿并发症的显著影响因素，不受统计调整的影响[粗比值比（OR），1.436；95%置信区间（CI），0.803 - 2.569；P = 0.223，相比调整后OR，1.406；95%CI，0.748 - 2.643；P = 0.290]。本研究结果表明，母亲使用来曲唑进行促排卵与较差的出生结局、先天性异常风险增加或新生儿并发症无关。
